Philipp Morakis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Philipp Morakis has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Irina Surovtsova
Clinical State Registry Baden-Württemberg GmbH, Baden-Württemberg Cancer Registry, 70191 Stuttgart, Germany
5 shared publications Irina Surovtsova
Clinical State Registry Baden‐Württemberg GmbH Baden‐Württemberg Cancer Registry (BWCR) Stuttgart Germany
4 shared publicationsDaria B. Kokh
Baden-Wuerttemberg Cancer Registry (BWCR), Clinical State Registry Baden-Wuerttemberg GmbH, Stuttgart, Germany
3 shared publicationsAndré Pfob
Department of Obstetrics and Gynecology Heidelberg University Hospital Heidelberg Germany
2 shared publications- Christiane Bauer-Auch
Quality Conferences Office at the Clinical State Registry Baden-Württemberg GmbH, Baden-Württemberg Cancer Registry, 70191 Stuttgart, Germany
2 shared publications Claudia Winzler
Geschäftsstelle Qualitätskonferenzen bei der Klinischen Landesregisterstelle Baden-Württemberg GmbH, Krebsregister Baden-Württemberg, Stuttgart, Deutschland
2 shared publications
Latest Publications
- Open Access
Pleomorphic Dermal Sarcoma: Clinical Characteristics, Surgical Management, and Long-Term Outcomes in a Large Registry-Based Cohort
Background: Pleomorphic dermal sarcoma (PDS) is a rare, cutaneous sarcoma predominantly affecting sun-exposed skin in elderly patients. Surgical excision remains the mainstay of treatment, but evidence on optimal management and long-term outcomes is limited. Methods: We retrospectively analyzed 1069 patients diagnosed with PDS between 2009 and 2025 using data from the Baden-Württemberg Cancer Registry, Germany. Patient characteristics, surgical management, resection status, and preceding malignancies were evaluated. Temporal surgical trends were assessed using multivariable logistic regression. Overall survival (OS) was analyzed using Kaplan–Meier estimates and multivariable Cox regression. Results: Median age was 82 years, and 83.7% of patients were male. The hair-bearing scalp was the most frequent tumor site (55.0%). Among 449 patients with documented surgical procedures, 82.0% underwent micrographically controlled surgery (MGC), with increasing use over time (adjusted OR per year, 1.19; 95% CI, 1.11–1.29). R0-resections were comparable between MGC and conventional resection (75.7% vs. 71.6%). Among 679 patients evaluated for preceding malignancies, 39.7% had a documented cancer history, including 4.4% with hematologic malignancies. Among 723 patients with reliable follow-up, median OS was 72.4 months (95% CI, 61.3–82.1). Mortality was strongly associated with age, but not anatomical tumor site. Surgical approach was not significantly associated with OS after adjustment (MGC vs. conventional resection: HR, 1.49; 95% CI, 0.95–2.3; p = 0.083). Conclusions: This large registry-based study provides real-world evidence on PDS management and prognosis. The increasing adoption of MGC supports its growing role in clinical practice, while the high frequency of preceding malignancies highlights the complex oncological history of patients with PDS.
Open AccessPleomorphic Dermal Sarcoma: Clinical Characteristics, Surgical Management, and Long-Term Outcomes in a Large Registry-Based Cohort
Background: Pleomorphic dermal sarcoma (PDS) is a rare, cutaneous sarcoma predominantly affecting sun-exposed skin in elderly patients. Surgical excision remains the mainstay of treatment, but evidence on optimal management and long-term outcomes is limited. Methods: We retrospectively analyzed 1069 patients diagnosed with PDS between 2009 and 2025 using data from the Baden-Württemberg Cancer Registry, Germany. Patient characteristics, surgical management, resection status, and preceding malignancies were evaluated. Temporal surgical trends were assessed using multivariable logistic regression. Overall survival (OS) was analyzed using Kaplan–Meier estimates and multivariable Cox regression. Results: Median age was 82 years, and 83.7% of patients were male. The hair-bearing scalp was the most frequent tumor site (55.0%). Among 449 patients with documented surgical procedures, 82.0% underwent micrographically controlled surgery (MGC), with increasing use over time (adjusted OR per year, 1.19; 95% CI, 1.11–1.29). R0-resections were comparable between MGC and conventional resection (75.7% vs. 71.6%). Among 679 patients evaluated for preceding malignancies, 39.7% had a documented cancer history, including 4.4% with hematologic malignancies. Among 723 patients with reliable follow-up, median OS was 72.4 months (95% CI, 61.3–82.1). Mortality was strongly associated with age, but not anatomical tumor site. Surgical approach was not significantly associated with OS after adjustment (MGC vs. conventional resection: HR, 1.49; 95% CI, 0.95–2.3; p = 0.083). Conclusions: This large registry-based study provides real-world evidence on PDS management and prognosis. The increasing adoption of MGC supports its growing role in clinical practice, while the high frequency of preceding malignancies highlights the complex oncological history of patients with PDS.
- Open Access
Real-World Emulation of Landmark Lung Cancer Trials: A Registry-Based Reconstruction of KN189, KN407, IMpower133, and PACIFIC
Background: Checkpoint inhibitors (CPIs) improve the survival in advanced NSCLC and ES-SCLC, but reproducibility of randomized trial results in routine practice remains unclear. Target trial emulation enables approximation of randomized trial designs using observational data while reducing common biases. Methods: Using the Baden-Württemberg Cancer Registry, we emulated four pivotal trials: KEYNOTE-189 (eKN189), KEYNOTE-407 (eKN407), IMpower133 (eIMP133), and PACIFIC (ePACIFIC). The eligibility criteria, treatment strategies, and outcomes were aligned with the original trials as closely as possible within registry constraints. Time-zero was defined as the treatment initiation for systemic therapy cohorts (eKN189, eKN407, eIMP133) and as completion of chemoradiotherapy for ePACIFIC. The treatment groups were balanced using propensity-score-based inverse probability weighting. The outcomes included the overall survival (OS) and the objective response rate (ORR). Results: A total of 4015 patients were included (eKN189: 1762; eKN407: 467; eIMP133: 1190; ePACIFIC: 595). After weighting, the baseline covariates were well balanced. ICI-based regimens were associated with an improved survival: eKN189: HR—0.59 (95% CI: 0.52–0.66), 5-year OS—22.7% vs. 4.7%; eKN407: HR—0.69 (95% CI: 0.54–0.89), 5-year OS—11.8% vs. 6.6%; eIMP133: HR—0.7 (95% CI: 0.62–0.79), 5-year OS—12.8% vs. 5.3%; ePACIFIC: HR—0.51 (95% CI: 0.39–0.66), 5-year OS—47.3% vs. 23.4%. The OS curves demonstrated long-term plateaus across CPI-containing arms. The ORRs were consistently higher with CPI-containing regimens (eKN189: 41.6% vs. 29.6%; eKN407: 44.8% vs. 31.5%; eIMP133: 51.7% vs. 43.1%; ePACIFIC: 56.6% vs. 47.1%). Conclusions: This registry-based target trial emulation reproduced the survival patterns observed in four landmark lung cancer RCTs within trial-like real-world populations, supporting the external validity of pivotal immunotherapy trials while reinforcing the role of high-quality registries as a powerful complement to randomized trials in oncology.
Open AccessReal-World Emulation of Landmark Lung Cancer Trials: A Registry-Based Reconstruction of KN189, KN407, IMpower133, and PACIFIC
Background: Checkpoint inhibitors (CPIs) improve the survival in advanced NSCLC and ES-SCLC, but reproducibility of randomized trial results in routine practice remains unclear. Target trial emulation enables approximation of randomized trial designs using observational data while reducing common biases. Methods: Using the Baden-Württemberg Cancer Registry, we emulated four pivotal trials: KEYNOTE-189 (eKN189), KEYNOTE-407 (eKN407), IMpower133 (eIMP133), and PACIFIC (ePACIFIC). The eligibility criteria, treatment strategies, and outcomes were aligned with the original trials as closely as possible within registry constraints. Time-zero was defined as the treatment initiation for systemic therapy cohorts (eKN189, eKN407, eIMP133) and as completion of chemoradiotherapy for ePACIFIC. The treatment groups were balanced using propensity-score-based inverse probability weighting. The outcomes included the overall survival (OS) and the objective response rate (ORR). Results: A total of 4015 patients were included (eKN189: 1762; eKN407: 467; eIMP133: 1190; ePACIFIC: 595). After weighting, the baseline covariates were well balanced. ICI-based regimens were associated with an improved survival: eKN189: HR—0.59 (95% CI: 0.52–0.66), 5-year OS—22.7% vs. 4.7%; eKN407: HR—0.69 (95% CI: 0.54–0.89), 5-year OS—11.8% vs. 6.6%; eIMP133: HR—0.7 (95% CI: 0.62–0.79), 5-year OS—12.8% vs. 5.3%; ePACIFIC: HR—0.51 (95% CI: 0.39–0.66), 5-year OS—47.3% vs. 23.4%. The OS curves demonstrated long-term plateaus across CPI-containing arms. The ORRs were consistently higher with CPI-containing regimens (eKN189: 41.6% vs. 29.6%; eKN407: 44.8% vs. 31.5%; eIMP133: 51.7% vs. 43.1%; ePACIFIC: 56.6% vs. 47.1%). Conclusions: This registry-based target trial emulation reproduced the survival patterns observed in four landmark lung cancer RCTs within trial-like real-world populations, supporting the external validity of pivotal immunotherapy trials while reinforcing the role of high-quality registries as a powerful complement to randomized trials in oncology.
- Open Access
Sebaceous Carcinoma: A Retrospective Multicenter Analysis of 213 Cases
Background: Sebaceous carcinoma (SC) is a rare malignant cutaneous malignancy. Methods: A multicenter retrospective study of 213 German patients with SC diagnosed between 2008 and 2024 was conducted. Data were extracted from the Baden-Württemberg Cancer Registry. Cases were separated into ocular and extraocular SC. Their demographic, clinical, and treatment-related characteristics were compared and influences on overall survival (OS) analyzed. Results: Most patients were elderly (median age: 79 years), with a male-to-female ratio of 2:1. Extraocular SC was more common in men, while ocular SC was more frequent in women. Most tumors were diagnosed at stage I, and microscopically controlled excision was the primary treatment modality (81.4%). Sentinel lymph node biopsy (2.3%), lymph node dissection (1.9%) and systemic therapy (1.4%) were only documented in a minority of cases. Survival analysis (median follow-up 3.2 years) revealed a median OS of 61.4 months in the entire cohort. No significant survival difference was observed between ocular and extraocular SC (64.8 vs. 53.7 months; p = 0.490), and multivariable analysis confirmed no prognostic impact of tumor localization (HR 1.4, 95% CI 0.85–2.4). Age was the only independent predictor of outcome, with strongly increased risk in patients aged 70–79 years (HR 4.4, 95% CI 1.01–19.2) and ≥80 years (HR 16.1, 95% CI 3.91–66.1). Prior malignancies, including MTS-like tumors and hematological neoplasms, were not independently associated with overall survival. Conclusions: In this multicenter cohort, sebaceous carcinoma showed no survival difference between ocular and extraocular disease, with age emerging as the main independent prognostic factor. Prior malignancies and tumor characteristics, including histologic grade, were not independently associated with outcome. Microscopically controlled excision appears to be an effective treatment option.
Open AccessSebaceous Carcinoma: A Retrospective Multicenter Analysis of 213 Cases
Background: Sebaceous carcinoma (SC) is a rare malignant cutaneous malignancy. Methods: A multicenter retrospective study of 213 German patients with SC diagnosed between 2008 and 2024 was conducted. Data were extracted from the Baden-Württemberg Cancer Registry. Cases were separated into ocular and extraocular SC. Their demographic, clinical, and treatment-related characteristics were compared and influences on overall survival (OS) analyzed. Results: Most patients were elderly (median age: 79 years), with a male-to-female ratio of 2:1. Extraocular SC was more common in men, while ocular SC was more frequent in women. Most tumors were diagnosed at stage I, and microscopically controlled excision was the primary treatment modality (81.4%). Sentinel lymph node biopsy (2.3%), lymph node dissection (1.9%) and systemic therapy (1.4%) were only documented in a minority of cases. Survival analysis (median follow-up 3.2 years) revealed a median OS of 61.4 months in the entire cohort. No significant survival difference was observed between ocular and extraocular SC (64.8 vs. 53.7 months; p = 0.490), and multivariable analysis confirmed no prognostic impact of tumor localization (HR 1.4, 95% CI 0.85–2.4). Age was the only independent predictor of outcome, with strongly increased risk in patients aged 70–79 years (HR 4.4, 95% CI 1.01–19.2) and ≥80 years (HR 16.1, 95% CI 3.91–66.1). Prior malignancies, including MTS-like tumors and hematological neoplasms, were not independently associated with overall survival. Conclusions: In this multicenter cohort, sebaceous carcinoma showed no survival difference between ocular and extraocular disease, with age emerging as the main independent prognostic factor. Prior malignancies and tumor characteristics, including histologic grade, were not independently associated with outcome. Microscopically controlled excision appears to be an effective treatment option.
- Open Access
- 6 November 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (1) , 102770
Use of bevacizumab for patients with International Federation of Gynecology and Obstetrics stage IIIB to IV epithelial ovarian cancer undergoing primary debulking surgery and its association with oncologic outcomes: a Cancer Registry study
- 6 November 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (1) , 102770
Open AccessUse of bevacizumab for patients with International Federation of Gynecology and Obstetrics stage IIIB to IV epithelial ovarian cancer undergoing primary debulking surgery and its association with oncologic outcomes: a Cancer Registry study
- Open Access
- 5 May 2025
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 312 (2) , 547-554
Clinical routine care for choriocarcinoma: a descriptive analysis of data from the Baden-Wuerttemberg Cancer Registry (BWCR)
Purpose Choriocarcinoma is a rare tumour. In Germany, due to its low incidence and lack of centralisation in care, only limited data are available on real-world clinical practice. This study aims to analyse tumour characteristics, treatment, and outcomes of patients with gestational choriocarcinoma using data from the Baden-Wuerttemberg Cancer Registry (BWCR), Germany. Methods We included patients aged 18-50 years diagnosed with choriocarcinoma between 2015 and 2023, reported to the BWCR. The cases were identified using ICD-O-3 codes 9100/3, 9101/3 and ICD-10-GM code C58.9. Diagnostic and treatment information was derived from standardised registry entries and pathology reports. First-line treatment was defined as therapy initiated within 120 days of diagnosis. Data were analysed using descriptive statistics. Results 38 patients (mean age 33.4 years) were included; 39% presented with metastatic disease, predominantly isolated lung metastases (67%). Systemic therapy was reported in 28 cases: MTX (n = 10), EMA-CO (n = 12), and - due to timecourse or substance - other regimens (n = 6). The reported treatment duration ranged from 20 - 120 days (MTX) and 50 -154 days (EMA-CO). One MTX-treated patient (10%) required escalation to EMA-CO. Among EMA-CO cases, therapy was discontinued in three patients and one second-line treatment reported. The reported adverse events were in line with published data. Conclusion This population-based analysis provides real-world insights into choriocarcinoma care in Baden-Wuerttemberg. While outcomes align with current guidelines, observed resistance to MTX and EMA-CO highlights the need for individualised treatment and closer monitoring. These findings underline the value of registry data in guiding therapy optimization—even in rare diseases like choriocarcinoma.
- 5 May 2025
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 312 (2) , 547-554
Open AccessClinical routine care for choriocarcinoma: a descriptive analysis of data from the Baden-Wuerttemberg Cancer Registry (BWCR)
Purpose Choriocarcinoma is a rare tumour. In Germany, due to its low incidence and lack of centralisation in care, only limited data are available on real-world clinical practice. This study aims to analyse tumour characteristics, treatment, and outcomes of patients with gestational choriocarcinoma using data from the Baden-Wuerttemberg Cancer Registry (BWCR), Germany. Methods We included patients aged 18-50 years diagnosed with choriocarcinoma between 2015 and 2023, reported to the BWCR. The cases were identified using ICD-O-3 codes 9100/3, 9101/3 and ICD-10-GM code C58.9. Diagnostic and treatment information was derived from standardised registry entries and pathology reports. First-line treatment was defined as therapy initiated within 120 days of diagnosis. Data were analysed using descriptive statistics. Results 38 patients (mean age 33.4 years) were included; 39% presented with metastatic disease, predominantly isolated lung metastases (67%). Systemic therapy was reported in 28 cases: MTX (n = 10), EMA-CO (n = 12), and - due to timecourse or substance - other regimens (n = 6). The reported treatment duration ranged from 20 - 120 days (MTX) and 50 -154 days (EMA-CO). One MTX-treated patient (10%) required escalation to EMA-CO. Among EMA-CO cases, therapy was discontinued in three patients and one second-line treatment reported. The reported adverse events were in line with published data. Conclusion This population-based analysis provides real-world insights into choriocarcinoma care in Baden-Wuerttemberg. While outcomes align with current guidelines, observed resistance to MTX and EMA-CO highlights the need for individualised treatment and closer monitoring. These findings underline the value of registry data in guiding therapy optimization—even in rare diseases like choriocarcinoma.
- 18 September 2024
- Published by Wiley in International Journal of Cancer
- Vol. 156 (3) , 587-597
Use of chemotherapy and loco‐regional therapy in stage IA triple‐negative breast cancer and their association with oncologic outcomes: A cancer registry study
We aimed to evaluate the role of adjuvant chemotherapy and loco‐regional therapy for stage IA (pT1, pN0) triple‐negative breast cancer (TNBC) in a real‐world setting. We identified patients with pT1, pN0 TNBC diagnosed between 2009 and 2021 within the Baden‐Württemberg cancer registry (BWCR), Germany. Overall survival (OS) was assessed using Kaplan–Meier statistics and multivariate Cox regression models (adjusted for age, use of chemotherapy, local therapy (breast conserving therapy [breast conserving surgery + radiotherapy] vs. mastectomy), and tumor histologic subtype). A total of 1231 patients with a median follow‐up of 45.9 months were identified: 1.0% (12 of 1231) with pT1mi stage, 9.5% (117 of 1231) with pT1a, 23.7% (292 of 1231) with pT1b, and 65.8% (810 of 1231) with pT1c. Multivariate Cox regression analysis revealed no significant influence for the use of chemotherapy on OS in pT1b patients (HR 0.90, 95% CI 0.43–1.90). For pT1c patients with Grade 1–2 tumors, the use of chemotherapy was not significantly associated OS (HR 1.01, 95% CI 0.48–2.11) but breast conserving therapy was associated with improved OS (HR 0.41, 95% CI 0.18–0.93). For pT1c patients with Grade 3 tumors, the use of chemotherapy (HR 0.51, 95% CI 0.33–0.78) as well as breast conserving therapy (HR 0.42, 95% CI 0.23–0.76) was associated with OS. This data suggests that OS in stage IA TNBC is strongly influenced by local therapy rather than the use of chemotherapy, except for pT1c patients with Grade 3 tumors. Larger studies with longer‐term follow‐up are welcomed to fully inform this discussion.
- 18 September 2024
- Published by Wiley in International Journal of Cancer
- Vol. 156 (3) , 587-597
Use of chemotherapy and loco‐regional therapy in stage IA triple‐negative breast cancer and their association with oncologic outcomes: A cancer registry study
We aimed to evaluate the role of adjuvant chemotherapy and loco‐regional therapy for stage IA (pT1, pN0) triple‐negative breast cancer (TNBC) in a real‐world setting. We identified patients with pT1, pN0 TNBC diagnosed between 2009 and 2021 within the Baden‐Württemberg cancer registry (BWCR), Germany. Overall survival (OS) was assessed using Kaplan–Meier statistics and multivariate Cox regression models (adjusted for age, use of chemotherapy, local therapy (breast conserving therapy [breast conserving surgery + radiotherapy] vs. mastectomy), and tumor histologic subtype). A total of 1231 patients with a median follow‐up of 45.9 months were identified: 1.0% (12 of 1231) with pT1mi stage, 9.5% (117 of 1231) with pT1a, 23.7% (292 of 1231) with pT1b, and 65.8% (810 of 1231) with pT1c. Multivariate Cox regression analysis revealed no significant influence for the use of chemotherapy on OS in pT1b patients (HR 0.90, 95% CI 0.43–1.90). For pT1c patients with Grade 1–2 tumors, the use of chemotherapy was not significantly associated OS (HR 1.01, 95% CI 0.48–2.11) but breast conserving therapy was associated with improved OS (HR 0.41, 95% CI 0.18–0.93). For pT1c patients with Grade 3 tumors, the use of chemotherapy (HR 0.51, 95% CI 0.33–0.78) as well as breast conserving therapy (HR 0.42, 95% CI 0.23–0.76) was associated with OS. This data suggests that OS in stage IA TNBC is strongly influenced by local therapy rather than the use of chemotherapy, except for pT1c patients with Grade 3 tumors. Larger studies with longer‐term follow‐up are welcomed to fully inform this discussion.
- Open Access
- 6 May 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (7) , 4381-4392
Oncologic Outcomes for Different Axillary Staging Techniques in Patients with Nodal-Positive Breast Cancer Undergoing Neoadjuvant Systematic Treatment: A Cancer Registry Study
Background: Targeted approaches such as targeted axillary dissection (TAD) or sentinel lymph node biopsy (SLNB) showed false-negative rates of < 10% compared with axillary lymph node dissection (ALND) in patients with nodal-positive breast cancer undergoing neoadjuvant systemic treatment (NAST). We aimed to evaluate real-world oncologic outcomes for different axillary staging techniques. Methods: We identified nodal-positive breast cancer patients undergoing NAST from 2016 to 2021 from the state cancer registry of Baden-Wuerttemberg, Germany. Invasive disease-free survival (iDFS) was assessed using Kaplan–Meier statistics and multivariate Cox regression models (adjusted for age, ypN stage, ypT stage, and tumor biologic subtype). Results: A total of 2698 patients with a median follow-up of 24.7 months were identified: 2204 underwent ALND, 460 underwent SLNB (255 with ≥ 3 sentinel lymph nodes [SLNs] removed, 205 with 1–2 SLNs removed), and 34 underwent TAD. iDFS 3 years after surgery was 69.7% (ALND), 76.6% (SLNB with ≥ 3 SLNs removed), 76.7% (SLNB with < 3 SLNs removed), and 78.7% (TAD). Multivariate Cox regression analysis showed no significant influence of different axillary staging techniques on iDFS (hazard ratio [HR] for SLNB with < 3 SLNs removed 0.96, 95% confidence interval [CI] 0.62–1.50; HR for SLNB with ≥ 3 SLNs removed 0.86, 95% CI 0.56–1.3; HR for TAD 0.23, 95% CI 0.03–1.64; ALND reference), and for ypN+ (HR 1.92, 95% CI 1.49–2.49), triple-negative breast cancer (HR 2.35, 95% CI 1.80–3.06), and ypT3-4 (HR 2.93, 95% CI 2.02–4.24). Conclusion: These real-world data provide evidence that patient selection for de-escalated axillary surgery for patients with nodal-positive breast cancer undergoing NAST was successfully adopted and no early alarm signals of iDFS detriment were detected.
- 6 May 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (7) , 4381-4392
Open AccessOncologic Outcomes for Different Axillary Staging Techniques in Patients with Nodal-Positive Breast Cancer Undergoing Neoadjuvant Systematic Treatment: A Cancer Registry Study
Background: Targeted approaches such as targeted axillary dissection (TAD) or sentinel lymph node biopsy (SLNB) showed false-negative rates of < 10% compared with axillary lymph node dissection (ALND) in patients with nodal-positive breast cancer undergoing neoadjuvant systemic treatment (NAST). We aimed to evaluate real-world oncologic outcomes for different axillary staging techniques. Methods: We identified nodal-positive breast cancer patients undergoing NAST from 2016 to 2021 from the state cancer registry of Baden-Wuerttemberg, Germany. Invasive disease-free survival (iDFS) was assessed using Kaplan–Meier statistics and multivariate Cox regression models (adjusted for age, ypN stage, ypT stage, and tumor biologic subtype). Results: A total of 2698 patients with a median follow-up of 24.7 months were identified: 2204 underwent ALND, 460 underwent SLNB (255 with ≥ 3 sentinel lymph nodes [SLNs] removed, 205 with 1–2 SLNs removed), and 34 underwent TAD. iDFS 3 years after surgery was 69.7% (ALND), 76.6% (SLNB with ≥ 3 SLNs removed), 76.7% (SLNB with < 3 SLNs removed), and 78.7% (TAD). Multivariate Cox regression analysis showed no significant influence of different axillary staging techniques on iDFS (hazard ratio [HR] for SLNB with < 3 SLNs removed 0.96, 95% confidence interval [CI] 0.62–1.50; HR for SLNB with ≥ 3 SLNs removed 0.86, 95% CI 0.56–1.3; HR for TAD 0.23, 95% CI 0.03–1.64; ALND reference), and for ypN+ (HR 1.92, 95% CI 1.49–2.49), triple-negative breast cancer (HR 2.35, 95% CI 1.80–3.06), and ypT3-4 (HR 2.93, 95% CI 2.02–4.24). Conclusion: These real-world data provide evidence that patient selection for de-escalated axillary surgery for patients with nodal-positive breast cancer undergoing NAST was successfully adopted and no early alarm signals of iDFS detriment were detected.
- 1 September 2023
- Published by Springer Nature in Die Onkologie
- Vol. 29 (10) , 1-6
Präzisionsonkologie in der Versorgungsrealität am Beispiel des Kolonkarzinoms
- 1 September 2023
- Published by Springer Nature in Die Onkologie
- Vol. 29 (10) , 1-6
Präzisionsonkologie in der Versorgungsrealität am Beispiel des Kolonkarzinoms
- Open Access
- 22 June 2023
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 32 (2) , 190-196
Clinical Characterization of HCC/CCA Mixed Cancers in a Population-based Cohort
Background and Aims: Primary liver cancer (PLC) ranks among of the most common cancers worldwide. Within this group, a minority of cases displays characteristics of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), known as combined hepatocellular cholangiocarcinoma (cHCC- CCA). Currently, there is no specific standardized therapy for these mixed tumors. Therefore, the aim of our study was to analyze the clinical course, treatment and outcome of cHCC-CCA patients in a European population-based registry. Methods: We investigated 9,144 patients with PLC (6,622 HCC, 2,356 iCCA, and 166 cHCC-CCA) diagnosed between 2009 and 2020. All data were obtained from Clinical Cancer Registry of Baden-Württemberg (BW), Germany. Results: In all three groups patients were predominantly male (82%, 57%, and 68% for HCC, iCCA and cHCC-CCA groups, respectively). 48% of cHCC-CCA patients were diagnosed as stage IV cancers, which was more than for HCC (31%) but less compared to CCA (64%). Overall median survival of cHCC-CCA patients was worse compared to HCC (9-13 months vs. 15.5 months, p<0.001) and rather comparable to CCA (11.8 months). Conclusions: Our data demonstrated that cHCC-CCA tumors appear to have a distinct clinical course with worse overall survival compared to HCC. Thus, identification of these cancers by histopathology is essential in order to further characterize this tumor entity and to provide accurate treatment to these patients.
- 22 June 2023
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 32 (2) , 190-196
Open AccessClinical Characterization of HCC/CCA Mixed Cancers in a Population-based Cohort
Background and Aims: Primary liver cancer (PLC) ranks among of the most common cancers worldwide. Within this group, a minority of cases displays characteristics of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), known as combined hepatocellular cholangiocarcinoma (cHCC- CCA). Currently, there is no specific standardized therapy for these mixed tumors. Therefore, the aim of our study was to analyze the clinical course, treatment and outcome of cHCC-CCA patients in a European population-based registry. Methods: We investigated 9,144 patients with PLC (6,622 HCC, 2,356 iCCA, and 166 cHCC-CCA) diagnosed between 2009 and 2020. All data were obtained from Clinical Cancer Registry of Baden-Württemberg (BW), Germany. Results: In all three groups patients were predominantly male (82%, 57%, and 68% for HCC, iCCA and cHCC-CCA groups, respectively). 48% of cHCC-CCA patients were diagnosed as stage IV cancers, which was more than for HCC (31%) but less compared to CCA (64%). Overall median survival of cHCC-CCA patients was worse compared to HCC (9-13 months vs. 15.5 months, p<0.001) and rather comparable to CCA (11.8 months). Conclusions: Our data demonstrated that cHCC-CCA tumors appear to have a distinct clinical course with worse overall survival compared to HCC. Thus, identification of these cancers by histopathology is essential in order to further characterize this tumor entity and to provide accurate treatment to these patients.
- 16 June 2022
- Published by Springer Nature in Forum
- p. 1-3
Wissenschaftliche Nutzung von Krebsregisterdaten bei seltenen Tumorerkrankungen am Beispiel des hepatischen Angiosarkoms
- 16 June 2022
- Published by Springer Nature in Forum
- p. 1-3
Wissenschaftliche Nutzung von Krebsregisterdaten bei seltenen Tumorerkrankungen am Beispiel des hepatischen Angiosarkoms